Copenhagen-based Xellia Pharmaceuticals acquired manufacturing facilities in Bedford, OH, from Hikma Pharmaceuticals. Included in the deal are several new manufacturing units for sterile injectables that are not currently operational. Hikma will retain the remaining facilities, including the Quality and Development Center, which has been operated by its subsidiary, West-Ward Injectables, since it acquired the site in 2014.
The site was previously owned by Ben Venue Laboratories which ceased manufacturing in December 2013. Xellia says it plans to invest significantly in the facilities to resume manufacturing in the new units at the site and in the establishment and training of a new organization to operate the plant.
Xellia plans to begin commercial production at the site within 24 months. The facility will operate alongside the company’s existing sterile injectables production plant in Raleigh, NC. The Bedford site significantly increases Xellia’s production capacity for sterile injectable products in the U.S. and enables future pipeline expansion, according to Carl-Åke Carlsson, CEO at Xellia.
“The U.S. is a very important market for us, and as a region with a strong manufacturing heritage and a uniquely skilled and specialized workforce, Bedford, Ohio is an ideal location to expand our manufacturing capabilities. Together with our production site and new U.S. headquarters in Raleigh, Xellia is in a great place to help make critical anti-infectives available to the patients that need them,” he said.
